Skip to main content

Market Overview

Vetr Crowd Upgrades Valeant

Share:

The Vetr community has upgraded Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from 3 stars to 3.5 stars.

The crowd is overall much more bearish on the name than Wall Street, with a price target of $14.26 compared to analyst consensus $24.58.

See how crowdsourced ratings can help predict the market?

Valeant shares closed at $12.92 Monday.

For the crowd's full analysis of the stock, click here.

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2018TD SecuritiesDowngradesBuyHold
Jun 2018BarclaysUpgradesEqual-WeightOverweight
May 2018MizuhoUpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

 

Related Articles (VRX)

View Comments and Join the Discussion!

Posted-In: VetrUpgrades Crowdsourcing Analyst Ratings General

Latest Ratings

StockFirmActionPT
SHNWFMorgan StanleyUpgrades
ICLRTruist SecuritiesUpgrades280.0
MNSTEvercore ISI GroupUpgrades
USPHBarrington ResearchDowngrades
BYNDCanaccord GenuityMaintains155.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com